Literature DB >> 6991774

Change in alkaline phosphatase isoenzyme pattern in urine as possible marker for renal disease.

G Pfleiderer, M Baier, A W Mondorf, T Stefanescu, J E Scherberich, H Müller.   

Abstract

The human kidney contains two types of alkaline phosphatase (AP) isoenzymes: a hepatic type of AP and an intestinal-like AP. Intestinal-like AP, measured by immunotitration techniques, is a minor component (1 to 4%) of the total AP activity. It is found only in the particle-free fraction (cytoplasm) and is located, with immunofluorescent techniques, in some of the proximal convoluted tubules. Urinary AP activity is found after high-speed centrifugation in the supernatant (x 100,000g), as well as in the sediment, and may be extracted from the sediment after solubilization with n-butanol. Both types of these renal isoenzymes contribute to urinary AP activity. Biochemical characterization (effect of inhibitors, thermostability, denaturing with urea, and so on) revealed that urinary intestinal-like AP and renal intestinal-like AP are identical. Both, however, have been distinguished as multiple forms of AP from the small intestine. Most of the urinary AP activity of healthy persons (22 volunteers) was found in the sediment and consisted of liver-type AP. Urinary AP of patients with diseases, after application of potentially nephrotoxic drugs or during rejection episodes of renal allografts, contains little sediment activity, but it contains increased amounts of urinary intestinal-like AP.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6991774     DOI: 10.1038/ki.1980.28

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  7 in total

Review 1.  Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD.

Authors:  Mathias Haarhaus; Vincent Brandenburg; Kamyar Kalantar-Zadeh; Peter Stenvinkel; Per Magnusson
Journal:  Nat Rev Nephrol       Date:  2017-05-15       Impact factor: 28.314

Review 2.  Alkaline Phosphatase: An Old Friend as Treatment Target for Cardiovascular and Mineral Bone Disorders in Chronic Kidney Disease.

Authors:  Mathias Haarhaus; Giuseppe Cianciolo; Simona Barbuto; Gaetano La Manna; Lorenzo Gasperoni; Giovanni Tripepi; Mario Plebani; Maria Fusaro; Per Magnusson
Journal:  Nutrients       Date:  2022-05-19       Impact factor: 6.706

3.  Alkaline phosphatase isoenzymes in human kidney and urine, immunohistochemical, immunological and biochemical characterization.

Authors:  G Pfleiderer; E Mössner; R Schenk
Journal:  Histochemistry       Date:  1984

4.  Alkaline phosphatase isozymes of serum and urine and urinary protein in young men before and after running 3 km.

Authors:  T Sato; H Sugimoto; W X Yan; K Endo; M Yamamoto
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1994

5.  Expression of intestinal alkaline phosphatase in human organs.

Authors:  U Domar; B Nilsson; V Baranov; U Gerdes; T Stigbrand
Journal:  Histochemistry       Date:  1992-12

6.  Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity.

Authors:  C Bokemeyer; L M Fels; T Dunn; W Voigt; J Gaedeke; H J Schmoll; H Stolte; H Lentzen
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

7.  Association between serum alkaline phosphatase and renal outcome in patients with type 2 diabetes mellitus.

Authors:  Lijun Zhao; Lin Li; Honghong Ren; Yutong Zou; Rui Zhang; Shanshan Wang; Huan Xu; Jie Zhang; Fang Liu
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.